S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
LON:DPH

Dechra Pharmaceuticals PLC (DPH.L) Share Forecast, Price & News

GBX 3,570
-32.00 (-0.89 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
3,475
Now: GBX 3,570
3,623.36
50-Day Range
3,182
MA: GBX 3,383.89
3,602
52-Week Range
2,030
Now: GBX 3,570
3,652
Volume225,456 shs
Average Volume258,147 shs
Market Capitalization£3.86 billion
P/E Ratio108.84
Dividend Yield0.98%
BetaN/A
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Dechra Pharmaceuticals PLC (DPH.L) logo

MarketRank

Overall MarketRank

0.71 out of 5 stars

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1606-814730
Employees1,889

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£515.10 million
Cash FlowGBX 209.91 per share
Book ValueGBX 590.20 per share

Profitability

Miscellaneous

Market Cap£3.86 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableNot Optionable
GBX 3,570
-32.00 (-0.89 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals PLC (DPH.L)'s stock been impacted by COVID-19?

Dechra Pharmaceuticals PLC (DPH.L)'s stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DPH stock has increased by 44.4% and is now trading at GBX 3,570.
View which stocks have been most impacted by COVID-19
.

Is Dechra Pharmaceuticals PLC (DPH.L) a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals PLC (DPH.L) in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dechra Pharmaceuticals PLC (DPH.L) stock.
View analyst ratings for Dechra Pharmaceuticals PLC (DPH.L)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dechra Pharmaceuticals PLC (DPH.L)?

Wall Street analysts have given Dechra Pharmaceuticals PLC (DPH.L) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dechra Pharmaceuticals PLC (DPH.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Dechra Pharmaceuticals PLC (DPH.L)'s next earnings date?

Dechra Pharmaceuticals PLC (DPH.L) is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Dechra Pharmaceuticals PLC (DPH.L)
.

How often does Dechra Pharmaceuticals PLC (DPH.L) pay dividends? What is the dividend yield for Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) declared a dividend on Monday, September 7th. Investors of record on Thursday, November 5th will be paid a dividend of GBX 24 per share on Friday, November 27th. This represents a dividend yield of 0.73%. The ex-dividend date is Thursday, November 5th. This is a positive change from Dechra Pharmaceuticals PLC (DPH.L)'s previous dividend of GBX 10.29. The official announcement can be seen at this link.
View Dechra Pharmaceuticals PLC (DPH.L)'s dividend history
.

Is Dechra Pharmaceuticals PLC (DPH.L) a good dividend stock?

Dechra Pharmaceuticals PLC (DPH.L) pays an annual dividend of GBX 34 per share and currently has a dividend yield of 0.98%. The dividend payout ratio of Dechra Pharmaceuticals PLC (DPH.L) is 103.66%. Payout ratios above 75% are not desirable because they may not be sustainable.
View Dechra Pharmaceuticals PLC (DPH.L)'s dividend history.

What price target have analysts set for DPH?

4 brokerages have issued 1-year price objectives for Dechra Pharmaceuticals PLC (DPH.L)'s stock. Their forecasts range from GBX 2,510 to GBX 3,515. On average, they expect Dechra Pharmaceuticals PLC (DPH.L)'s stock price to reach GBX 3,077.50 in the next year. This suggests that the stock has a possible downside of 13.8%.
View analysts' price targets for Dechra Pharmaceuticals PLC (DPH.L)
or view Wall Street analyst' top-rated stocks.

Who are some of Dechra Pharmaceuticals PLC (DPH.L)'s key competitors?

What other stocks do shareholders of Dechra Pharmaceuticals PLC (DPH.L) own?

Who are Dechra Pharmaceuticals PLC (DPH.L)'s key executives?

Dechra Pharmaceuticals PLC (DPH.L)'s management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 59, Pay $793k)
  • Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 41, Pay $375.6k)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 57, Pay $466k)
  • Dr. Susan Longhofer, Chief Scientific Officer (Age 62)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 50)
  • Ms. Melanie Hall, Company Sec.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock symbol?

Dechra Pharmaceuticals PLC (DPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals PLC (DPH.L)?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,570.

How big of a company is Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) has a market capitalization of £3.86 billion and generates £515.10 million in revenue each year. Dechra Pharmaceuticals PLC (DPH.L) employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals PLC (DPH.L)'s official website?

The official website for Dechra Pharmaceuticals PLC (DPH.L) is www.dechra.com.

How can I contact Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L)'s mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.